Sees FY25 Adjusted EBITDA $590M-$605M, or 28.2% to 31.5% growth; Pharmacy Segment Revenue $10.750B-$11.100B, or 22.8% to 26.8% growth; Provider Segment Revenue $1.450B-$1.500, or 10.0% to 13.8% growth. For the FY25, BrightSpring is increasing guidance, which excludes the Community Living business and the effects of any future closed acquisitions. All growth rates are shown as compared to the full year 2024 Revenue and Adjusted EBTIDA results, excluding the Community Living business.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BTSG:
- BTSG Upcoming Earnings Report: What to Expect?
- Wells says CMS proposed rates worse than expected, final rate likely to improve
- Home health stocks under pressure following proposed rate cuts
- BrightSpring Health initiated with a Buy at TD Cowen
- BrightSpring Health Services Executive Resignation Announced